Upcoming Investor Events

RNS Number : 7885K

Open Orphan PLC

02 September 2019

 

02 September 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Upcoming Investor Events

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 4^th September to 10^th October 2019.

Cathal Friel, Open Orphan's Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company's business plans for 2019-2020.

No new material information will be disclosed at any event.

A full schedule of the upcoming events is as follows:

Event	Date/Time	Location
Shares Magazine Investor Evening	September 4th 2019 18:00 - 21:30	London - Novotel Tower Bridge, EC3N 2NR
ShareSoc Growth Company Seminar	September 11th 2019 17:30	London - 65 Gresham Street, London, EC2V 7NQ
London South East Biotech Investor Evening	September 11th 2019 18:30	London - Brewers Hall, Aldermanbury Square, London EC2V 7HR
Shares Magazine Investor Evening	September 12th 2019 17:20 - 21:30	Edinburgh - Radisson Blu Hotel, EH1 1TH
Total Market Solutions	September 18th 2019 12:30-15:00	London, Moorgate
Proactive Investors One2One Forum	September 18th 2019 18:00 - 20:00	London - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB in the Charles Suite (1st Floor)
Shares Magazine Investor Evening	October 10th 2019 18:00	Manchester - Macdonald Manchester Hotel, M1 2PG

Enquiries:

Open Orphan Plc Tel: [phone]
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

 

END

 

 

NRAEAKPEDAPNEFF